主页 > 医学信息 >
【medical-news】抗氧化剂影响放化疗效果 癌症患者
Tue May 27, 2008 5:06pm EDT
NEW YORK (Reuters Health) - Cancer patients should perhaps avoid taking antioxidant supplements, a review of clinical trial data suggests, because they may diminish the effectiveness of chemotherapy and radiation treatment.
Still, findings from different studies are conflicting, so further research is warranted to determine whether antioxidants can be safely taken during cancer therapy and whether they have any benefit.
Although research looking at antioxidant use during cancer treatment has been on-going on for nearly two decades, it remains a controversial topic, note Dr. Brian D. Lawenda, from the Navel Medical Center in San Diego, California, and colleagues in their article in the Journal of the National Cancer Institute.
In researching the impact of antioxidant use on radiation therapy, the team identified three clinical studies that specifically addressed the topic.
Results from the largest of the three trials suggested that antioxidant therapy reduced overall survival. However, there was evidence indicating that one antioxidant, amifostine, can protect certain healthy tissues from radiation damage without increasing resistance in cancerous tissue.
Sixteen trials were identified that looked at the effects of antioxidant supplements on chemotherapy. There was no evidence that antioxidants reduced treatment response rates, although the authors warn that none of the studies were really large enough to address this properly.
"Despite some intriguing studies that have suggested the benefit of adjunctive antioxidant treatments in cancer patients, the totality of the available evidence is equivocal at best and leaves us with serious concerns about the potential for harm," Lawenda's team concludes.
SOURCE: Journal of the National Cancer Institute, online May 27, 2008.
http://www.reuters.com/article/healthNews/idUSTON77595620080527 本人以认领，若48小时没有完成，请其他战友认领 广谱细胞保护药--氨磷汀amifostine是一种细胞保护剂类药物，用于减少由环磷酰胺和顺铂治疗晚期孵巢癌所引起的与中性白细胞有关的感染危险。对大多数抗肿瘤细胞毒类药物或放射治疗所产生的毒副作用，能明显保护正常细胞免受损害，而不影响其搞肿瘤活性。这个药物值得关注. 楼主我来一篇相同的报道
Cancer patients should avoid the routine use of antioxidant supplements during radiation and chemotherapy because the supplements may reduce the anticancer benefits of therapy, researchers concluded in a commentary published online in the Journal of the National Cancer Institute.
Radiation and many chemotherapy agents work to kill cells by inducing free radicals that damage DNA and proteins. Therefore, there is a possibility that taking antioxidant supplements, such as vitamin E or β-carotene may interfere with the therapies and reduce their anticancer activity. On the other hand, some investigators hypothesize that antioxidant supplementation may protect healthy tissues and reduce the side effects of treatment. Despite two decades of research into this question, no clear answer has appeared.
To evaluate the potential harms or benefits of antioxidant supplementation, Brian D. Lawenda, M.D., of the Naval Medical Center San Diego and colleagues reviewed all of the randomized trials they could identify that tested the effect of antioxidant supplements on radiation therapy or chemotherapy.
In the case of radiotherapy, they identified nine studies that addressed the question, including two meta-analyses. However, only three studies were randomized controlled trials designed to look at the clinical effect of antioxidant therapy on radiation. In the largest of the randomized trials, antioxidant supplementation was associated with a reduction in overall survival. One antioxidant agent, amifostine, which is already approved by the U.S. Food and Drug Administration to increase radioresistance in healthy salivary gland tissues, may protect normal tissues without increasing tumor radioresistance. Lawenda and colleagues caution that the question needs to be studied further before a solid conclusion can be made.
The authors identified 16 randomized controlled trials that examined the impact of antioxidant supplementation on chemotherapy. Six of the trials were placebo-controlled.
Of the studies that included information on response rates, none reported a decrease in response in the antioxidant arm of the trial compared with the control arm. However, Lawenda and colleagues caution that none of the trials was large enough to reliably detect such differences.
"Despite some intriguing studies that have suggested the benefit of adjunctive antioxidant treatments in cancer patients, the totality of the available evidence is equivocal at best and leaves us with serious concerns about the potential for harm," the authors write.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-14 17:11
医学,生命科学网